KRAS and non-small cell lung carcinoma: In a recent study, it has been speculated that the metabolic frailty of KRAS/LKB1 comutated NSCLC cells could be exploited pharmacologically by the combination of metformin with compounds that increase intracellular stress by interfering with DNA replication and repair, such as platinum compounds [72].